Aprea Therapeutics reports FY2022 net loss of $112.7M; cash $28.8M, runway into Q3 2024

Aprea Therapeutics, Inc.

Cash and cash equivalents $28.8M at Dec 31, 2022, down from $53.1M; with $5.5M public offering, runway into Q3 2024.
Q4 2022 net loss $2.4M ($0.92/share) vs $7.8M ($7.20/share) in Q4 2021; operating loss $2.7M vs $7.8M.
Full year 2022 net loss $112.7M ($67.99/share) including $76M acquired IPR&D, vs $37.1M in 2021.
R&D expenses fell to $0.5M in Q4 2022 from $4.5M as legacy trials wrapped; only one active trial vs six.
ATRN-119 Phase 1/2a enrolling; ATRN-1051 IND filing expected by end of 2023; AACR abstract selected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.